Teva- Pharmaceutical Industries's operating income is $2B.
Get informed when a big investor buys or sells
+ FollowAs of Jun 30, 2026
Trailing 12 months ending Jun 30, 2026
Teva- Pharmaceutical Industries (TEVA) currently reports a operating income of $2B as of June 2026. That compares with $890M in the prior-year period — up 121.9% year over year. Use the charts on this page to explore Teva- Pharmaceutical Industries's operating income history and peer comparisons.
Teva- Pharmaceutical Industries's operating income increased from $890M to $2B — a 121.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Teva- Pharmaceutical Industries reported $2B in operating income as of June 2026. That compares with $890M in the prior-year period — up 121.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current operating income of $2B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Teva- Pharmaceutical Industries, and consider following TEVA for alerts when major investors trade the stock.
Teva- Pharmaceutical Industries is classified in the Healthcare sector. On operating income, it currently shows $2B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TEVA with unrelated industries.